Kornimate/medical-research-clean huggingface dataset:
iris registry: intelligent research in sight registry

Conditions: Eye Diseases

Summary: the iris™ registry (intelligent research in sight) is the nation's first comprehensive eye disease clinical registry. the american academy of ophthalmology is developing it as part of the profession's shared goal of continual improvement in the delivery of eye care.the iris registry will be a centralized system for ophthalmology practices to promote practice innovations and achieve clinical excellence.

the iris registry is primarily a clinical self-improvement tool. it will allow ophthalmologists to compare their patient outcomes, professional performance and care processes against other ophthalmologists across the country. the iris registry will be able to measure the continuum of care from initial patient contact, through intervention and follow up. improve patient care - monitor patient interactions, track interventions, identify and address gaps in quality of care, and measure quality outcomes. manage patient populations - proactively manage clinical conditions for entire patient populations by running reports on specific care criteria. benchmark your practice - identify practice strengths and weaknesses using the iris registry's ophthalmology-specific clinical data from other practices to compare to the performance and outcomes data of your practice. run quality reports on demand - providing clinician- and practice-level results, plus national results and patient-level detail for all iris registry measures. enhance quality and practice efficiency - use the iris registry data to analyze practice processes and procedures and as a source for fact-based decision-making. because the iris registry will capture data over time at the individual and practice level, it will help practices efficiently manage patient care and optimize practice resources. join a community of quality - become a member of a like-minded community of quality-driven professionals striving to continuously improve patient care. interact with your peers to create opportunities for sharing quality improvement strategies and broaden your professional network.

Eligibility criteria:
inclusion criteria: * patients who meet the denominator requirements for each measure. exclusion criteria: * none

Keywords: eye diseases
comparing heavy levobupivacaine with enantiomeric excess of 50% and heavy racemic bupivacaine.

Conditions: Fracture of Lower Limb

Summary: the purpose of this study is to compare the non-inferiority between heavy levobupivacaine with enantiomeric excess of 50% and heavy racemic bupivacaine during spinal anesthesia for orthopedic procedures in the lower limbs.

the heavy levobupivacaine with enantiomeric excess of 50% was developed to be a safe local anesthetic replacing the heavy racemic bupivacaine. this study will evaluate the non-inferiority regarding efficacy and safety of spinal anesthesia in orthopedic procedures.

Eligibility criteria:
inclusion criteria: * asa (american society of anesthesiologists) i or asa ii * spinal anaesthesia for lower limb surgery * patient consent exclusion criteria: * relative or absolute contraindications for spinal anesthesia * history of hypersensitivity to the local anesthetics or components * opioids for anesthetic adjuvant * spinal lesions, peripheral neuropathies or any other neurologic disorders that leads to changes of sensitivity * body mass index = or \> 35 * lumbar puncture difficulty * ventricular extrasystoles * dementia, others loss of cognitive ability * difficulty in the spine * spinal cord surgery * anaphylactic reactions or stevens-johnson syndrome * polytraumatism * alcoholism abuse and use of illicit substance * changes in the blood test * others conditions judged by investigator's opinion
motivational interviewing integrated with social network counseling for teens

Conditions: Substance Use

Summary: the purpose of this research is to test the feasibility and efficacy of a brief (one session) preventative intervention using motivational interviewing integrated with social network counseling for substance use among adolescent patients in a primary care setting. one hundred participants will be randomly assigned to either motivational interviewing integrated with social network counseling or attention control conditions. the motivational interviewing integrated with social network counseling condition is expected to show improvement when compared to the attention control condition.


Eligibility criteria:
inclusion criteria: * 14-18 years old * resident of richmond va or greater richmond area * patient at virginia commonwealth university or richmond city department of health exclusion criteria: * ward of the state * not fluent in english * incapable of providing consent
mri evaluation of change in gluteal muscles following the treatment with hifem device

Conditions: Muscle Tone Increased

Summary: this study will use magnetic resonance imaging (mri) to evaluate changes in gluteal muscle following the treatment with hifem stimulation for aesthetic improvement of buttocks.


Eligibility criteria:
inclusion criteria: * age ≥ 21 years * voluntarily signed informed consent form * bmi ≤ 30 kg/m2 * women of child-bearing potential are required to use birth control measures during the whole duration of the study * subjects willing and able to abstain from partaking in any treatments other than the study procedure to promote body contouring during study participation * subjects willing and able to maintain his/her regular (pre-procedure) diet and exercise regimen without effecting significant change in either direction during study participation exclusion criteria: * cardiac pacemakers * implanted defibrillators, implanted neurostimulators * electronic implants * pulmonary insufficiency * metal implants * drug pumps * malignant tumor * fever * pregnancy * breastfeeding * following recent surgical procedures when muscle contraction may disrupt the healing process * application over areas of the skin which lack normal sensation * scars, open lesions and wounds at the treatment area * unrepaired abdominal hernia
observation of atelectasis using lung ultrasonography in children undergoing general anesthesia: the cohort study for evaluation of the relationship between the incidence and severity of upper respiratory tract infection and the magnitude of anesthesia-induced atelectasis

Conditions: Surgery

Summary: pediatric patients between 6months and 6years old will be included. they are scheduled for elective general or urologic surgery at a single tertiary medical center. before the operation, the researcher interviews the parents of the pediatric patients to check whether they have the upper respiratory tract infection and asks them to fill out a questionnaire about the severity of their symptoms. the researcher will get the symptom score of the upper respiratory tract infection in the questionnaire. the degree of anesthesia induced atelectasis is measured using lung ultrasound. pulmonary ultrasound is performed after endotracheal intubation and at the end of the operation dividing the patient's thorax into 12 regions. the investigator grades the degree of atelectasis at each region form 0 to 3 points. after the end of the operation, check whether the respiratory adverse effects occurred during emergence and recovery at the post anesthesia care unit.


Eligibility criteria:
inclusion criteria: * age: pediatric patients older than 6 months and younger than 6 years * scheduled for elective pediatric general or urology surgery. exclusion criteria: * undergoing laparoscopic surgery * pediatric patients with lower respiratory tract infection( pneumonia , bronchiolitis ) * patients with bronchopulmonary dysplasia history * hemodynamic instability
safety study of rpe65 gene therapy to treat leber congenital amaurosis

Conditions: Retinal Degeneration

Summary: the purpose of the study is to determine whether gene therapy is safe and effective for the treatment of severe childhood blindness caused by mutations in rpe65.

the main objective of the proposed trial is to determine the safety and efficacy subretinal administration of a recombinant adeno-associated viral vector (raav 2/2.hrpe65p.hrpe65) at three different dosage levels in individuals with autosomal recessive severe early-onset retinal degeneration due to mutations in rpe65. we have a comprehensive clinical monitoring plan to investigate the safety and efficacy of vector delivery.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of severe early-onset retinal dystrophy confirmed missense mutation(s) in rpe65 exclusion criteria: * visual acuity in the study eye better than 6/36 snellen * hypertension * diabetes mellitus * tuberculosis * renal impairment * immunocompromise * osteoporosis * gastric ulceration * severe affective disorder) * pregnancy or lactation

Keywords: retinal dystrophy leber congenital amaurosis rpe65 gene therapy
evaluation of the efficacy and safety of bempedoic acid (etc-1002) 180mg when added to pcsk9 inhibitor therapy

Conditions: Hypercholesterolemia

Summary: the purpose of this study is to determine if bempedoic acid (etc-1002) 180mg added to pcsk9 inhibitor (evolocumab) therapy is effective and safe in patients with elevated ldl cholesterol.


Eligibility criteria:
inclusion criteria: * age ≥18 years or legal age of majority depending on regional law * fasting, calculated ldl-c at screening ≥160 mg/dl and following pcsk9i therapy ≥70 mg/dl * men and nonpregnant, nonlactating women exclusion criteria: * heterozygous (hefh) or homozygous (hofh) familial hypercholesterolemia * total fasting tg ≥500 mg/dl * renal dysfunction or a glomerulonephropathy; egfr \<30 ml/min/1.73 m2 * known cardiovascular disease (cvd), peripheral arterial disease (pad), or cerebrovascular disease (cd) * history of type 1 or type 2 diabetes * uncontrolled hypertension * uncontrolled hypothyroidism * liver disease or dysfunction * gastrointestinal conditions or procedures (including lap-band® or gastric bypass) * history of hematologic or coagulation disorders * history of malignancy (except non-metastatic basal or squamous cell carcinoma of the skin and cervical carcinoma in situ) * unexplained creatine kinase (ck) \>3 × uln * use of a cholesterylester transfer protein (cetp) inhibitor in the last 12 months prior to screening, such as: anacetrapib, dalcetrapib, or evacetrapib * pregnant or breast feeding, or planning to become pregnant during treatment and/ or within 30 days after the end of treatment

Keywords: cholesterol pcsk9 repatha evolocumab ldl-c
sir-spheres study to calculate the radiation-absorbed dose of 99mtc-maa

Conditions: Carcinoma; Carcinoma, Hepatocellular; Liver Neoplasm

Summary: the goal of this interventional clinical trial is to evaluate the dose of radiation of technetium-99m macroaggregated-albumin (99mtc-maa) after an intra-arterial injection to the whole body and non-liver critical organs in patients who are undergoing evaluation for sir-spheres treatment for hepatocellular carcinoma.

the investigation is a prospective, single center, open label, single-arm study. patients enrolled in the study will have 3 imaging scans taken after 99mtc-maa injection, the final of which will occur between 18 and 24 hours post-injection.

Eligibility criteria:
inclusion criteria: 1. willing, able, and mentally competent to provide written informed consent 2. age 18 or older at the time of consent 3. patients who are being evaluated for sir-spheres treatment eligibility exclusion criteria: 1. patients who are contraindicated for sir-spheres treatment 2. patients who are contraindicated for 99mtc-maa per the manufacturer's package insert

Keywords: technetium-99m macroaggregated-albumin (99mtc-maa) sir-spheres y90 resin microspheres treatment
nebulized procaterol versus nebule salbutamol for the treatment of moderate acute asthma

Conditions: Moderate Acute Asthma

Summary: the purpose of this study is to compare the efficacy and safety of nebule procaterol with nebule salbutamol in the treatment of moderate acute asthma.


Eligibility criteria:
inclusion criteria: 1. patients with moderate acute asthma according to global initiative for asthma (gina) 1998 (appendix 1). patients with moderate acute asthma according to modified global initiative for asthma (gina) 1998 (patients with asthma score 5 - 11; pefr ≤ 80% predicted) 2. patients of both gender aged 15 to 60 years 3. patients still have the ability to undergo examinations and give written informed consent exclusion criteria: 1. pregnant and lactating women 2. smokers 3. patients with heart disease, hyperthyroidism, diabetes mellitus, copd or other chronic diseases 4. patients with signs of severe infections
preimplantation genetic testing for aneuploidy (pgt-a) in women aged 37-41 years

Conditions: Infertility

Summary: a multinational multi-centre, randomized, controlled non-blinded trial with participation of three fertility clinics in denmark and one in spain to assess the efficacy and safety of preimplantation genetic testing for aneuploidy (pgt-a) in 37-41-year-old women.


Eligibility criteria:
inclusion criteria: * women aged 37-41 years with a male partner, a female partner og undergoing fertility with no partner. * anti müllerian hormone (amh) ≥6.28 pmol/l (amh should be measured no more than one year prior to study inclusion). the optimal is to use the elecsys® assay. if other assays are used this should be reported to the investigator and the amh cut-off level may appropriately be changed so that it corresponds to the cut-off used in the elecsys® assay. * ivf/icsi cycle number 1-5 (previous ivf/icsi cycles will not count if the woman is recruited after an ivf/icsi/fet-delivery). exclusion criteria: * pgt-sr or pgt-m. * testicular sperm aspiration (tesa), testicular sperm extraction (tese), micro-tese (or cryopreserved sperm from these procedures). * males with severely compromised semen quality (\<1 million progressively motile sperm cells following gradient centrifugation). * endometriosis stage three or four. * women with severe thyroid disease (women can be included if they have normal thyroid levels on relevant medication). * severe co-morbidity; diabetes mellitus type 1 (dm1), mb crohn or colitis ulcerosa, systemic lupus erythematosus (sle), hiv, hepatitis b/c, or dysregulated thyroid disease. * ≥2 previous art treatment without blastocyst formation.
evaluate the post-marketing efficacy and safety of eptq s and eptq lidocaine s

Conditions: Nasolabial Folds; Mid Face Volume Loss; Lip Volume Enhancement

Summary: this study in multi-center, prospective and observational study. the purpose of this study is to observe effects and safety of hyaluronic acid filler series, eptq s and eptq lidocaine s, for facial volume and folds.

participants for this study are treated with eptq s and eptq lidocaine s for smoothing nasolabial folds or volumizing mid-face or lips. treating period is around 24 weeks. facial volume and wrinkle condition, participants' satisfaction, and safety would be assessed.

Eligibility criteria:
inclusion criteria: * male and female adults aged 19 years and older. * meet one of the following among individuals who want temporary improvement of facial wrinkles and volume. 1. wrinkle severity rating scale score 3 or 4 for nasolabial fold. 2. mid-face volume deficit scale score 3 or greater. 3. medicis lip fullness scale score 1-2. in cases of 2-1) and 2-2), participants must meet both sides (right and left) to be eligible for enrollment. for 3), the medicis lip fullness scale scores 1-2 at the target sites for procedures (upper lip, lower lip, up \& down) eligible for enrollment * voluntarily agree to participate in this observational study in written consent form. exclusion criteria: * received anti-thrombotics (except low-dose aspirin \[100 mg, maximum 300 mg/day\]) within 2 weeks from screening. * currently have or have a history of bleeding disorder. * applied graft/prosthesis or biomaterials, including hyaluronic acid, polycaprolactone, collagen filler, lifting (threads, laser, etc.), and botulinum toxin, at the site for indication within 24 weeks from screening. * skin disorder or wound infection on the face that affects this study * have history of side effects of emla cream or equivalent lidocaine agent. * history of hypersensitivity to hyaluronic acid agent(s). * other contraindications as per the \[precautions for use\] in the approved label for the study device. * determined as not eligible for the study by the investigator.

Keywords: hyaluronic acid filler facial region
ebv-associated diffuse large b cell lymphoma

Conditions: To Characterize and Compare Clinical, Pathological and Molecular Features

Summary: the aim of this study is to characterize and compare clinical, pathological (histology, immunophenotype) and molecular features of ebv-related gzl and dlbcl: do they belong to the same entity or to two different subtypes of ebv-related lymphoma ?

recent progresses in the understanding of lymphoma biology allowed the identification of new categories in the who classification of lymphoid neoplasm. among these new entities, grey zone lymphoma (gzl) between classical hodgkin lymphoma and diffuse large b cell lymphoma entered the classification as a provisional entity in 2008 and diffuse large b cell lymphoma (dlbcl) ebv-associated not otherwise specified in patient without history of immunodepression in 2016. these entities need however to be further characterized as no clear pathological definition and distinction between ebv related gzl and ebv related dlbcl are proposed in the literature. after primary infection that occurs in almost 80% of young adult population in western country, ebv latency state settles in a small portion of b cells. the virus is known to promote b-cells proliferation and transformation through complex mechanisms. ebv-associated lymphoproliferative disorders have already been largely studied in immunocompromised host (human immunodeficiency virus, congenital immunodeficiency, immunosuppressor and post-transplant lymphoproliferative disorder, e.g.), but its role is largely unknown in patients with no history of immunodeficiency. whether these patients arbor an underlying type of immune deficiency has not yet been established, even though immunosenecence in elderly or immaturity of the immune system in children has been postulated in those population. based on former definition, ebv-associated lymphoproliferation were usually the apanage of classical hodgkin lymphoma (chl) or immunodeficiency-associated lymphoproliferative disorders. however, as published recently, several different histological patterns with intermediate features between primary mediastinal b cell lymphoma (pmbcl) and classical hodgkin lymphoma (chl), namely grey zone lymphoma (gzl), but also diffuse large b cell lymphoma (dlbcl) were described to be ebv-associated. on the clinical point of view, patients with gzl are young and have a poor prognosis. data regarding ebv+ dlbcl are discordant and further studies are warranted, even though initial report concluded to a poor prognosis for these patients.

Eligibility criteria:
inclusion criteria: * all ebv-related gzl and dlbcl in immunocompetent patients * age minimum: 18 years old exclusion criteria: * another diagnosis than ebv-related gzl and dlbcl * \<18 years old

Keywords: ebv, dlbcl
strength training for older breast cancer survivors

Conditions: Breast Neoplasm; Osteoporosis, Postmenopausal

Summary: women aged 50 and older are disproportionately affected by breast cancer, not only in terms of new diagnoses, but also in terms of survivorship. approximately 85% of women who receive a first diagnosis of breast cancer are aged 50 and over, thus older women constitute the largest group of breast cancer survivors. yet, few studies have focused on evaluating whether physical activity and exercise interventions affect long-term symptoms, physical fitness and function, and body composition of older breast cancer survivors. due to the combined effects of breast cancer, related treatments and aging it is likely that exercise is even more beneficial for older breast cancer survivors than for younger survivors. along with the cancer-related symptom of fatigue common to cancer survivors, older survivors face age-related declines in bone and muscle mass, muscle strength, bone health and physical function (gait and balance) that are likely exacerbated by reduced physical activity in survivorship and side effects of adjuvant cancer treatment. all women, regardless of age, are at risk for breast cancer recurrence. recent epidemiologic evidence suggests a link between exercise and reduced risk of cancer recurrence in breast cancer survivors. strength training is specifically suited to reverse or slow age-related declines in bone, muscle, strength and function and has shown promise to reduce cancer-related fatigue. however, no controlled trials of strength training in older breast cancer survivors have been conducted.


Eligibility criteria:
inclusion criteria: * diagnosed with early stage breast cancer at age of 50 or older * completed adjuvant therapy, radiation +/- chemotherapy but selective estrogen receptor modulators (serms), (aromatase inhibitors (ais) ok) at least 1 year prior to enrollment exclusion criteria: * cognitive difficulties that preclude answering the survey questions, participating in performance testing or giving informed consent * diagnosed osteoporosis * current regular participation in planned impact activities or resistance training (more than 2 times a week for 30 minutes at a time) * medication that contraindicates participation in moderate intensity strength training or previous use of medications known to affect bone metabolism * movement or neurologic disorder, not including chemo-induced peripheral neuropathy

Keywords: randomized clinical trial elderly cancer survivor bone health body composition signs and symptoms
role of andi-d in dengue fever: a pilot study

Conditions: Dengue Fever

Summary: the purpose of this study is evaluate the role of anti-d in dengue fever.

this study was conducted in pgimer. patients presenting with fever and thrombocytopenia in emergency medical opd / medicine opd were screened and all dengue serology positive patients were evaluated for enrolment into the study. we had proposed to enroll 30 patients with diagnosed dengue haemorrhagic fever. the diagnosis of the dengue fever was based upon the clinical history ,general physical examination and the lab tests : thrombocytopenia ( platelet count ≤ 20,000 ) ,and a positive dengue serology. study design : it was an open label inteventional study . one group of 15 patients ( intervention group ) received platelet support along with injection anti-d in a dose of 50 µg/kg (250iu/kg) intravenously while the other group of 15 ( control group) received platelet support only . a base line platelet count of all the participant of both the study groups was taken and then the level of platelets at 12 , 24 , 36 , and 48hr post treatment initiation was noted. the patients were followed till the time of discharge .

Eligibility criteria:
inclusion criteria: * fever and thrombocytopenia with/without bleeding manifestations * dengue serology positive patients * platelet count ≤ 20,000/mm3 * rh positive patients * willing to give written informed consent exclusion criteria: * dengue serology positive but platelet count \> 20,000/mm3 * rh negative patients * pregnant females